CDH4

Across TCGA pan-cancer cohorts, CDH4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDH4 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CDH4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDH4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

GBM, UCEC, and CCRCC are the cancer types where CDH4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.287	0.474	.008	10	view →
UCEC	DFS	Tertile	All	1.000	0.176	.036	4	view →
CCRCC	DFS	Tertile	All	0.622	0.892	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CDH4–GBM (DFS)

Open the GBM breakdown →